Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM



    OXFORD, England, April 24 /CNW/ - PharmaVentures Ltd, announced today
that it has been engaged by Merck & Co, Inc. to advise and assist in divesting
its world class research centre, the IRBM, located near Rome, Italy. The
engagement will utilise PharmaVentures' pharmaceutical transactions experience
in the healthcare and investment business sectors. The IRBM is an integrated,
state-of-the-art small molecule and biological discovery centre. IRBM has an
outstanding record of drug discovery including Isentress(R), the first
approved HIV integrase inhibitor and winner of the Prix Galien USA 2008 award
for the best pharmaceutical agent. The centre has received significant
investment since 2000 and is staffed with exceptional, experienced
pharmaceutical scientists.
    Dr Fintan Walton, CEO, PharmaVentures commented, "This research centre is
a rare opportunity for a pharmaceutical company or contract research
organisation to expand its operations and gain access to one of the world's
foremost research centres."

    A leading results driven organisation, PharmaVentures
(http://www.pharmaventures.com) assists pharmaceutical and biotechnology
companies across the world in all aspects of deal making. The Company's core
business is the provision of tailored consulting and transaction advisory
services to the Life Science industry, with additional deal making support
provided through the PharmaDeals(R) range of intelligence products which
include analysis tools and reports. An innovative business, PharmaVentures
additionally provides industry insight, business reviews and deal making
trends through the world's first online pharmaceutical television channel
http://www.pharmatelevision.com. Now in its 17th year, PharmaVentures is based
in Oxford, UK, employs over 50 people mostly educated to PhD or above. With
offices in the USA and Australia, the Company works for a variety of clients
from start-ups to global corporate pharmaceutical companies.





For further information:

For further information: Lisa Holloway, Marketing, +44(0)1865-784-177,
lisa.holloway@pharmaventures.com

Organization Profile

PHARMAVENTURES LTD

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890